Unibest

Pharmaceutical intermediates

Seladelpar Intermediates

2 pharmaceutical intermediates for Seladelpar. Indication: Biliary cirrhosis; Cholangitis sclerosans.

Submit a ProjectAll intermediates

About Seladelpar

Originator
Cymabay Therapeutics Inc
Indication
Biliary cirrhosis; Cholangitis sclerosans
Approved Date
08/14/2024
NCE Patent
08/14/2029
DS/DP
08/02/2025

Available intermediates

2 intermediates currently listed for Seladelpar. Request specifications, documentation or a quotation for any item below.

Seladelpar intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(S)-2-((4-(TRIFLUOROMETHYL)PHENOXY)METHYL)OXIRANE\ \ \ \ \ \ 256372-58-4\ \ \ \ \ \\ \ \ \ \ \
Ethyl 2-(4-(chlorosulfonyl)-2-methylphenoxy)acetate91427-62-2//

Other programs under S

SaracatinibSarecycline HydrochlorideSarolanerSaxagliptinSeltorexantSemaglutideSitafloxacin hydrate Sofosbuvir

Building toward Seladelpar?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →